DIA Japan Annual Meeting Event

November 12, 2017 | 9:30AM  -  November 14, 2017 | 5:00PM  (GMT+09:00) Tokyo Standard Time

​Tokyo Japan (View map)


Today we stand on the threshold of the Age of Big Data and Artificial Intelligence (AI); soon we can expect world-class medical databases to enable dramatic advances in drug safety and in research and development. The structural reforms mandated by Abenomics (the economic policies championed by the current Japanese Prime Minister Abe) are pushing government and industry to develop strategic policies in information and communications technology (ICT) that will promote innovation in areas such as medical treatment. Meanwhile, the popular media report novel treatment options for patients through genetic analysis, and new horizons for regenerative medicine technology. All of this has raised expectations for further developments in medical treatment.

Last year's topic was "Breakthrough in Regulatory Science for Patient-Engaged Medical Treatment." This year we continue our focus on advances in patient-centric drug development, with special emphasis on how AI and Big Data, particularly therapeutic and genomic information, will affect the development of next-generation medicines.  Our 2017 keynote speakers, Professor Tomohiro Sawa of Teikyo University, and 2016 Nobel laureate in Physiology or Medicine Professor Yoshinori Ohsumi of Tokyo Institute of Technology, are uniquely qualified to address these areas.